Efficacy of ondansetron and lorazepam in controlling emesis associated with cytotoxic chemotherapy

Abstract

A phase II study using a combination of Ondansetron and Lorazepam to treat patients receiving either highly or moderately emetogenic chemotherapy regimens has recently been completed. A total of 56 patients were enrolled and data from 53 is amenable to analysis. The overall response rates were 100% and 91% for the highly and moderately emetogenic regimens respectively, with 16 out of 20 patients (80% and 18 out of 33 patients (54.5% achieving a complete or major response respectively. Toxicity was mild and no dose modifications were necessary. ©1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.